1 August 2019 - Bayer’s Xarelto (rivaroxaban) can be funded by the NHS to prevent strokes and heart attacks in high-risk adults with coronary artery disease, NICE has said.

In final draft guidance NICE recommended use of Xarelto at a dose of 2.5mg daily combined with aspirin, as an option for preventing atherothrombotic events in adults with coronary artery disease (CAD), or symptomatic peripheral artery disease (PAD), who are at high risk of ischaemic events.

NICE’s recommendation is based on evidence from the phase 3 COMPASS study, which was stopped early after meeting its primary efficacy endpoint.

Read Pharmaphorum article